Taysha Gene Therapies, Inc.
Clinical-stage company developing AAV-based gene therapies for severe CNS diseases.
TSHA | US
Overview
Corporate Details
- ISIN(s):
- US8776191061
- LEI:
- Country:
- United States of America
- Address:
- 3000 PEGASUS PARK DRIVE, 75247 DALLAS
- Website:
- https://tayshagtx.com/
Description
Taysha Gene Therapies, Inc. is a clinical-stage company focused on developing and commercializing adeno-associated virus (AAV)-based gene therapies. The company's primary mission is to eradicate severe and life-threatening monogenic diseases that affect the central nervous system (CNS). Its therapeutic approach involves using AAV vectors to deliver functional genes to target cells, addressing the root cause of genetic disorders. Taysha maintains a pipeline of gene therapy programs in various stages of development. A key candidate, TSHA-102, is being investigated for the treatment of Rett syndrome and has received Breakthrough Therapy designation from the U.S. Food and Drug Administration.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-04 13:12 |
8-K - Taysha Gene Therapies, Inc. (0001806310) (Filer)
|
English | 147.2 KB |
Automate Your Workflow. Get a real-time feed of all Taysha Gene Therapies, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Taysha Gene Therapies, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Taysha Gene Therapies, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
